菜单
返回新闻列表dafabet黄金手机版新闻
头条 | dafabe888手机版登录完成B轮融资,夯实创新抗体药发现领先地位
时间:2021.06.26 作者:dafabe888手机版登录 来源:dafabe888手机版登录

2021年6月26日,上海,领先的创新抗体药物发现公司---dafabe888手机版登录(上海)有限公司(以下简称“dafabe888手机版登录”或“公司”)宣布完成B轮融资。本轮融资由领航新界资本与摩天石投资共同领投,惠远资本及老股东遂真投资共同跟投,领航新界投资合伙人兰志银先生于融资后进入dafabe888手机版登录董事会。在此之前,dafabe888手机版登录已于2020年5月获得海尔医疗和之江生物共同完成的A轮融资。


dafabe888手机版登录成立于2015年,聚焦于创新抗体药物研发。公司以“运用创新抗体药物提升人们的生活品质”为愿景,以“让天下没有难做的创新抗体药”为使命;持续打造全球领先的创新抗体药高通量及一体化研发平台,积累并形成了全球最大的抗体库等技术资源;公司一方面提供领先的服务,另一方面全力协同合作伙伴研发病患急需的创新抗体药物。


经过6年的持续深耕,dafabe888手机版登录已经建立了先进、完善的创新抗体药物发现一体化研发平台,为全球150多家制药公司和药品研发单位提供了数百项独具特色的创新抗体药发现项目打包研发服务和阶段技术服务,并与全球10多家公司展开了10多个项目的协同研发。



dafabe888手机版登录CEO郎国竣博士表示:“非常感谢新老投资人对公司的认可和支持。公司将充分利用本轮融资,扩充研发及服务团队,加速完成一系列万亿抗体库的上线,并构建出‘模块化、自动化和集成化’高效组合的、国际领先的创新抗体药一体化研发服务平台,彻底解决顶级创新抗体药候选分子‘一将难求’的难题,彻底打通‘从靶点到药品IND’的各个环节,让所有有志于创新抗体药研发的公司或个人,都能充分利用dafabet黄金手机版的开放式平台,实现新药研发梦想。”

 

投资人寄语

领航新界投资合伙人兰志银表示:“领航新界坚持长期价值投资,积极促进中国企业的创新与成长,推动产业的进步与发展。dafabe888手机版登录在抗体药发现领域深耕多年,已建立完善的创新抗体药物一体化研发平台,拥有领先的创新抗体药物发现能力。我们非常高兴能参与本轮投资,助力dafabe888手机版登录打造国际领先的创新抗体药研发服务平台。”


摩天石投资负责人曾应华表示:“摩天石长期关注创新抗体药物领域的前沿进展。dafabe888手机版登录聚焦于创新抗体药物的研发服务,贯彻服务与协同研发的双重业务机制。我们高度认可dafabet黄金手机版团队的技术能力及执行效率,我们相信dafabe888手机版登录能够协助中国药企推动中国药物研发。”


惠远资本总裁张珊珊表示:“创新抗体药物是生物医药中发展最快的赛道之一,具有长期投资价值。dafabe888手机版登录深耕在创新抗体药物的研发和服务多年,拥有国际领先的一体化抗体药研发技术能力,同时也在不断加强自身的研发平台建设。我们非常认可dafabe888手机版登录管理团队的专注和执行力,作为本轮的投资人,将一起助力dafabet黄金手机版不断突破,实现更多的里程碑,相信公司一定能为整个抗体药物研发行业带来巨大的赋能和贡献。”


逐真控股合伙人翁翠表示:“遂真投资作为逐真控股股权投资的业务板块,长期看好新药研发大赛道,已三轮加持dafabe888手机版登录。作为dafabe888手机版登录的早期股东,我们一直非常认可dafabet黄金手机版核心团队在抗体药研发领域的创新精神与战略决策,也见证了dafabe888手机版登录的快速成长历程。我们将长期坚定地支持dafabe888手机版登录的发展,期待dafabet黄金手机版的平台和技术为创新抗体药物研发带来新的突破。”


关于领航新界

领航新界资本成立于2018年,创始团队经验丰富,兼具国际水准,擅长赋能型投资,凭借对智能科技、生物医疗2大赛道的专业专注,依托领航生态中专业孵化器、美元基金、人民币基金的完整布局,打造出有竞争力的差异化VC创新模式,投资成果斐然。投资的多家企业在A股和纳斯达克成功上市,IRR回报率在行业内名列前茅。同时,领航新界也是一家深度参与价值创造的资本产业公司,坚持长期价值投资,横跨中美两地,以资本为手段完成产业整合,积极促进中国企业的创新与成长,推动产业的进步与发展。领航新界携手投资人为创业者提供有力的支持,共同打造世界级公司。


关于摩天石投资

摩天石投资控股有限公司成立于2009年12月,是广东广润集团有限公司旗下的股权投资平台,主要投资于包括医药、大健康、人工智能、芯片在内的各个领域的创业、创新项目,覆盖VC、产业投资和PE投资,是集团产业生态的重要构成部分。广润集团旗下拥有多家医药制造企业、保健品企业、创投公司、产业孵化基地,集团控股的下属的生产、研发的医药子公司于2017年在创业板成功上市。


关于惠远资本

惠远资本成立于2019年,由专业投资团队与国资共同设立,是一家专注于生物医药和医疗器械领域长期投资的新锐医疗投资机构,系统布局细分赛道中具有突破性和创新性技术的优质标的。与多家产业机构建立深入合作关系,坚持以“产业赋能+资本助力”为投资策略,旨在为投资者带来长期稳健的投资回报。


关于逐真投资

遂真投资为上海逐真投资控股有限公司(逐真控股)股权投资的业务板块,公司成立于2017年,是浙江大学参股的重要投资平台。公司股东均为浙大校友及浙大系相关企业,包括浙大网新、浙大控股(浙大友创)、多位上市公司实际控制人,以及资深投资专家、互联网创业精英及社会知名人士等。公司以“在路上”的创业心态,秉持“求是精神”,整合全球校友资源:通过平台运作,促进校友之间及校友与母校之间的合作,助力产融结合;通过凝聚创新创业资源,以开放合作的理念为优秀企业的发展提供澎湃动力;通过市场化运作推动产业转型升级,力求实现多方共赢。


关于dafabe888手机版登录

dafabe888手机版登录是一家国际领先的、专注于创新抗体药物研发和服务的生物高技术企业。


公司致力于打造国际领先的创新抗体药高质量、高通量、集成化研发及价值转化平台,构建治疗、研发和诊断类产品与服务的业务生态系统,协同全球生物制药、诊断及药物研发公司,打开人类疾病诊断和治疗的新局面。


公司自成立以来,一直保持着快速发展。截至2021年5月,公司有专业团队160多人,其中博士及硕士比例超过70%,团队拥有完整的创新药物研发及产业化经验。公司已在“上海漕河泾国家高科技园区”建立了数千平方米、设施设备先进的创新抗体药物一体化研发实验室,拥有以系列超千亿噬菌体展示抗体库为代表的、涵盖创新抗体药物发现、抗体工程改造、体内外药效筛选、抗体药物成药性分析、生产用细胞株构建、生产工艺开发等10大功能模块和40多个核心技术平台。


公司持续推出“品质最佳、速度最快、性价比最高”的新技术、新产品、新服务和新场景。公司已和全球150多家制药公司、药物研发机构、诊断试剂产品开发公司建立了友好的业务合作关系。


卓越创新、追求梦想、奋力拼搏、造福病患!dafabe888手机版登录期待与广大客户和合作伙伴一道,共同构建长期协同成长生态圈,共建健康社会。



Headline | Sanyou Biopharmaceutic-als completes series B financing and secures its leading role in innovative antibody drug discovery 


On June 26, 2021, Shanghai: Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and Montesy Investment, and followed by Grand Mount Capital and Seeking Capital (an existing investor). After this round of financing, Zhiyin Lan, venture partner of LH Ventures, will join the Board of Directors of Sanyou Bio. Previously, Sanyou Bio obtained joint series-A funding from Haier Biomedical and Shanghai Liferiver Bio-Tech in May 2020.


Established in 2015, Sanyou Bio focuses on R&D of innovative antibody drugs. The Company’s vision is to improve quality of life with innovative antibody drugs, and their mission is to empower the industry to develop any innovative antibody drug. Sanyou Bio have been continuously building a world-leading high-throughput integrated R&D platform for innovative antibody drugs, collecting technical resources to establish the largest antibody library in the world. While providing leading services, Sanyou Bio have made every effort to collaborate with their partners to develop innovative antibody drugs to meet the patients’ need.


After 6 years of persistent endeavor, Sanyou Bio has established a state-of-the-art integrated R&D platform for innovative antibody drug discovery, provided hundreds of unique R&D solutions and technical services for innovative antibody drug discovery projects to more than 150 pharmaceutical companies and drug development institutions around the world, and carried out more than 10 collaborative R&D projects with more than 10 partners.


Dr. David (Guojun) Lang, CEO of Sanyou Bio, stated, "we are very grateful to our previous and new investors for their recognition and support. We will make the best use of this funding round to expand our R&D and service teams, expedite the launching process of a number of super-trillion antibody libraries, and build a world-leading modular, automated, and integrated innovative antibody drug integrated R&D service platform to overcome the difficulty of finding top-notch candidate molecules of innovative antibody drugs and clear the path from a target selection to IND application. We hope that all companies and individuals aspired to R&D of innovative antibody drugs can leverage fully with Sanyou Bio's open platform to achieve their pursuit of new drug development."

 

Investors' messages

Zhiyin Lan, venture partner of LH Ventures, stated, "LH Ventures commits to long-term value investment, actively promotes the innovation and growth of Chinese enterprises, and promotes industrial progresses and development. Sanyou Bio has devoted in antibody drug discovery for years, and established a comprehensive integrated R&D platform and equipped with leading competence in innovative antibody drug discovery. We are very excited to join this round of investment to assist Sanyou Bio in building a world-leading R&D service platform for innovative antibody drugs."

Yinghua Zeng, chief investment officer of Montesy Investment stated, " Montesy has focused on forefront progresses in the area of innovative antibody drugs for a long time. Sanyou Bio focuses on R&D services of innovative antibody drugs and implements dual business patterns of services plus collaborative R&D. We highly recognize the technical competence and execution efficiency of Sanyou Bio's team. We believe that Sanyou Bio can assist Chinese pharmaceutical industry and promote drug development in China."


Shanshan Zhang, president of Grand Mount Capital, stated, "Innovative antibody drugs are one of the fastest growing sectors in biopharmaceutical industry, and have long-term investment values. Sanyou Bio has devoted in innovative antibody drug R&D and services for years, has world-leading technical competence in integrated antibody drug R&D, and has been continuously strengthening the construction of its own R&D platform. We highly recognize the dedication and execution capability of Sanyou Bio's management team. As one of the investors of this funding round, we will assist Sanyou Bio for its continuous breakthrough to reach more milestones. We believe that the Company will bring huge empowerment and contribution to the whole industry of antibody drug R&D."


Cui Weng, partner of Seeking Capital, stated, "Seeking Capital has strong confidence in new drug R&D in the long-term, that’s why we have invested in Sanyou Bio for three rounds. As one of the early shareholders, we have always appreciated the innovation and strategies of Sanyou Bio's core team in the antibody drug R&D field and we have witnessed its rapid growth since 2018. We will continue to firmly support the future development of Sanyou Bio and look forward to seeing Sanyou Bio's platform and technologies bringing new breakthroughs in the near future."


About LH Ventures

LH Ventures was established in 2018. The founding team has rich experience and world class skills in enabling investment. With its professional dedication to intelligent technologies and biomedical sectors, and reliance on the full layout of its ecosystem including professional incubators, USD funds and RMB funds, LH Ventures has built a competitive and differentiated VC innovation mode and achieved striking investment achievements. Several enterprises LH Ventures invested have been successfully listed in China A share and Nasdaq, with the highest IRRs ranking in the industry. Moreover, LH Ventures is also a capital investment company deeply involved in value creation. LH Ventures commits to long-term value investment across China and the United States, and has accomplished industry integration with capital, actively promoted innovation and growth of Chinese enterprises, and drove industrial progresses and development. Along with other investors, LH Ventures provides powerful support to entrepreneurs to build world-class companies together. 


About Montesy Investment

Established in December 2009, Montesy Investment Holding Co., Ltd. (Montesy Investment) is an equity investment platform under Guangdong Guangrun Group Co., Ltd. (hereafter referred to as Guangrun Group), mainly investing in entrepreneurship projects and innovation projects in fields including pharmaceuticals, big health industry, artificial intelligence, and integrated circuit. It’s business covers VC, industrial investment, and PE investment, and is an important part of the Group’s industrial ecosystem. Guangrun Group owns many pharmaceutical enterprises, nutraceutical enterprises, venture capital (VC) companies, and industrial incubation bases. A subsidiary of Guangrun Group specialized in pharmaceutical manufacture and R&D successfully went IPO in China Growth Enterprise Market in 2017.


About Grand Mount Capital

Grand Mount Capital (GMC) is a dedicated healthcare venture capital firm established by state-owned capital and investment professionals in 2019. GMC’s investment spans biopharmaceuticals, medical devices, and diagnostics. Adhering to the strategy of “Industry participation+capital assistance", GMC works closely with multiple healthcare conglomerates to add value to portfolio companies by providing active support in market access, collaborations, regulatory guidance, etc. GMC aims to deliver long-term and sustainable return for investors while becoming a trusted partner to entrepreneurs that aim to build great companies with breakthrough technologies.


About Seeking Capital

Established in 2017, Shanghai Seeking Capital Holding Co., Ltd. (Seeking Capital) is an innovative investment platform founded by Zhejiang University’s alumni. Its shareholders include Zhejiang University’s affiliated enterprises such as Insigma Group and Future Capital, CEOs of listed companies, investment professionals, industry experts and elite entrepreneurs. With "faith-of-truth spirit" entrepreneurial mindset, Seeking Capital embraces to integrate global resources of Zhejiang University, its alumni and beyond. Its investment portfolio mainly focuses on life science and healthcare, IT, and intelligent manufacturing industries. Through Seeking Capital’s integrative platform, it enables collaboration between the alumni and the alma mater, and assists in industry-finance integration. Seeking Capital further fuses innovation and entrepreneurship resources to provide surging power to start-up enterprises, drives industrial transformation and upgrading, and strives to achieve a win-win situation for multiple parties.


About Sanyou Biopharmaceuticals

Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.


The company is committed to establishing a leading high-quality, high-throughput, and integrated R&D and value transformation platform for innovative antibody drugs internationally, constructing a business ecosystem involving therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases.


Since its establishment 6 years ago, Sanyou Bio has maintained rapid development. As of May 2021, the company has more than 160 members in a professional team, of which the proportion of doctors and masters is more than 70%. The team has full experience in innovative drug development and industrialization. Sanyou Bio has established an integrated innovative antibody drug R&D laboratory of several thousand square meters with advanced facilities in "Shanghai Caohejing Hi-Tech Park". There are 10 major functional modules and more than 40 core technological platforms which are characterized by a series of sub-Trillion phage display antibody libraries, covering innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, antibody drug developability analysis, construction of cell lines for production, and manufacturing process development, etc.


The company is continuing to launch new technologies, new products, new services, and new scenarios of "the best quality, the fastest speed, and the highest cost performance". Friendly business cooperation relations have been established by the company with more than 150 pharmaceutical companies, drug R&D institutions, and diagnostic reagent and product development companies worldwide.


Excellence and innovation, pursuit of dreams, striving and envolving, for the benefit of patients! Sanyou Bio looks forward to jointly building a long-term collaborative growth ecosystem and a healthy society with our clients and partners.